{"product_id":"9783642823596","title":"Adjuvant Chemotherapy of Breast Cancer: Papers Presented at the 2nd International Conference on Adjuvant Chemotherapy of Breast Cancer, Kantonsspital St. Gallen, Switzerland, March 1 – 3, 1984","description":"\u003ch1\u003eAdjuvant Chemotherapy of Breast Cancer: Papers Presented at the 2nd International Conference on Adjuvant Chemotherapy of Breast Cancer, Kantonsspital St. Gallen, Switzerland, March 1 – 3, 1984\u003c\/h1\u003e \u003ch2\u003eSenn, Hans-Jörg\u003c\/h2\u003e \u003cp\u003eH.-J. Senn Adjuvant Chemotherapy (ACT) of breast cancer has now emerged as one of the controversial su):\u0026gt;jects in clinical and also experimental oncology. Driven by growing frustration about stagnating cure rates in breast cancer [1,4] and stimulated by elegant demonstration of highly curative effects of adjuvant systemic therapy in animal models [6, 11] and in several childhood neoplasias [15], researchers introduced ACT to the primary treatment of breast cancer with great hope some 15 years ago. After a first wave of isolated \"historic\" trials with generally limited but in one case remarkable success [5, 9], a second generation of ACT studies was initiated by NSABP investigators and oncology centers in Europe [2, 6, 13]. These trials were well conducted statistically and diagnostically, and all in the early 1970s included a surgical control arm. Early and intermediate beneficial effects on relapse-free survival (RFS) after 2-3 years median observation time then prompted a whole series of ACT studies in breast cancer. These \"third-gener­ ation\" studies usually regarded some positive influence of ACT as a given fact, dropping surgical control regimens and comparing different ACT regimens, hopefully in a prospective, randomized way 1984 Fig. 1. The mushrooming of adjuvant studies in breast cancer XII Introduction [reviews in 3, 14]. The \"mushrooming\" of ACT studies in breast cancer during the last 10 and especially 5 years is demonstrated in Fig. 1, and it gets really cumbersome even for the insider to keep on top of the multitude of sometimes conflicting data.\u003c\/p\u003e \u003ch3\u003eDetails\u003c\/h3\u003e \u003cp\u003ePublished by: Springer\u003c\/p\u003e \u003cp\u003ePublication Date: 2011-12-15\u003c\/p\u003e \u003cp\u003eFormat: Paperback\u003c\/p\u003e \u003cp\u003eISBN-13: 9783642823596\u003c\/p\u003e \u003cp\u003eDOI: 10.1007\/978-3-642-82357-2\u003c\/p\u003e \u003cp\u003eDimensions: 244.0cm x170.0cm\u003c\/p\u003e \u003cp\u003ePages: 246.0\u003c\/p\u003e ","brand":"Springer Berlin Heidelberg","offers":[{"title":"Default Title","offer_id":44422426460300,"sku":"9783642823596","price":98.99,"currency_code":"USD","in_stock":true}],"thumbnail_url":"\/\/cdn.shopify.com\/s\/files\/1\/0710\/9545\/1788\/files\/9783642823596.jpg?v=1768311936","url":"https:\/\/lateknightbooks.com\/products\/9783642823596","provider":"Late Knight Books and Services, LLC","version":"1.0","type":"link"}